Detalles de la búsqueda
1.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol
; 2024 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38556836
2.
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.
J Natl Compr Canc Netw
; 22(2D)2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38862005
3.
2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
Am J Hematol
; 99(5): 938-945, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38450790
4.
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol
; 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38804599
5.
BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience.
Int J Mol Sci
; 25(10)2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38791222
6.
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Haematologica
; 108(12): 3321-3332, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37408464
7.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880203
8.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633671
9.
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood
; 135(20): 1739-1749, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32160294
10.
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(9): 1033-1062, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36075392
11.
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
Am J Hematol
; 96(11): 1532-1538, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536293
12.
Biology and Current Treatment of Myeloproliferative Neoplasms.
Cancer Treat Res
; 181: 151-165, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626360
13.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Biol Blood Marrow Transplant
; 26(12): e322-e327, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866594
14.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(6): 1084-1090, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035275
15.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(8): 1425-1432, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416253
16.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant
; 26(2): 292-299, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536825
17.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Am J Hematol
; 95(10): 1193-1199, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32628327
18.
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Biol Blood Marrow Transplant
; 25(2): 287-292, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227232
19.
Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
Biol Blood Marrow Transplant
; 25(5): e183-e185, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30708188
20.
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 25(2): 265-269, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30201397